‘Holy grail’ sleep apnea pill can cut episodes by more than 50%
A new drug called AD109 may revolutionize the treatment of sleep apnea by significantly reducing episodes. Developed by Apnimed, this pill could replace cumbersome CPAP machines for millions of Americans suffering from the condition. If approved by the FDA, AD109 could be available as early as next year.
- ▪AD109 has shown to reduce the severity of sleep apnea symptoms by 47% after 26 weeks of use in clinical trials.
- ▪The drug combines oxybutynin and atomoxetine to help keep airways open during sleep.
- ▪Approximately 80 million Americans suffer from sleep apnea, with many patients non-compliant with CPAP machines.
Opening excerpt (first ~120 words) tap to expand
Health ‘Holy grail’ sleep apnea pill can cut episodes by more than 50% By Reda Wigle Published May 29, 2026, 5:35 p.m. ET See more of our coverage in your search results. Add The New York Post on Google A promising new drug could put an end to cumbersome CPAP machines and allow millions of Americans to breathe easy and sleep soundly. Researchers at the biopharm company Apnimed have been developing a sleep apnea drug called AD109. After various clinical trials, they are preparing to file for FDA approval. “A pill for sleep apnea has always been the holy grail,” Dr. Andrew Wellman, a Harvard sleep researcher, told Forbes, noting that over the past several years, at least 40 drug candidates have been tested for obstructive sleep apnea (OSA) without success.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at New York Post.
Discussion
0 commentsMore from New York Post
